Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 10,802 |
|
|||||
| News | (1) | ||||||
| Day High | 2.09 | Low High |
|||||
| Day Low | 1.95 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Dominari Holdings Inc | DOMH | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.09 | -4.39% | 1.96 | 16:30:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.08 | 1.95 | 2.09 | 1.96 | 2.05 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 272 | 10,802 | $ 2.03 | $ 21,896 | - | 1.76 - 3.40 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:10 | 29 | $ 1.96 | USD |
Dominari Holdings Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 8.71M | 5.35M | - | 2.04M | -22.88M | -4.28 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Dominari News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DOMH Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.13 | 2.21 | 1.95 | 2.13 | 6,117 | -0.17 | -7.98% |
| 1 Month | 2.09 | 2.49 | 1.95 | 2.18 | 8,074 | -0.13 | -6.22% |
| 3 Months | 2.20 | 3.20 | 1.95 | 2.57 | 12,015 | -0.24 | -10.91% |
| 6 Months | 2.01 | 3.20 | 1.9165 | 2.40 | 12,321 | -0.05 | -2.49% |
| 1 Year | 2.93 | 3.40 | 1.76 | 2.47 | 11,462 | -0.97 | -33.11% |
| 3 Years | 3.21 | 4.45 | 1.76 | 2.98 | 15,332 | -1.25 | -38.94% |
| 5 Years | 3.21 | 4.45 | 1.76 | 2.98 | 15,332 | -1.25 | -38.94% |
Dominari Description
| Dominari Holdings Inc formerly, AIkido Pharma Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing a antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. |
